<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GONADORELIN HYDROCHLORIDE</span><br/>(goe-nad-oh-rell'in)<br/><span class="topboxtradename">Factrel<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">diagnostic agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mcg/vial</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic luteinizing hormonereleasing hormone (LHRH) with structure identical to the natural hormone; also referred
         to as gonadotropin-releasing hormone (GnRH).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Stimulates anterior pituitary to release the gonadotropin LH.</p>
<h1><a name="uses">Uses</a></h1>
<p>To evaluate functional capacity and response of the gonadotropes of anterior pituitary and in suspected gonadotropic deficiency.
         Also used to evaluate residual gonadotropic function of the pituitary following surgical or radiologic removal of a pituitary
         tumor.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of delayed puberty, amenorrhea, and infertility in males.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Lactation; concurrent use of other drugs having effect on pituitary gonadotropic function; children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Evaluation of Functional Capacity of Anterior Pituitary</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC/IV</span> 100 mcg administered in women during early phase of menstrual cycle (days 1 7) if it can be determined<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Reconstitute 100-g vial with 1 mL sterile diluent (supplied by manufacturer), and the 500-g vial with 2 mL. Use immediately
            after preparation for best results.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute as for SC injection.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose by direct IV over 1530 s.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store ampule and reconstituted drug at room temperature. Use reconstituted drug within 24 h. Discard unused diluted solution
            and diluent.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, light-headedness. <span class="typehead"> GI:</span> Nausea, abdominal discomfort. <span class="typehead">Other:</span> Flushing, local inflammation at injection site if given SC, hypersensitivity reaction (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p> <span class="alt">Baseline LH levels</span> are elevated in menopausal and postmenopausal women. Patients clinically diagnosed or with suspected pituitary or hypothalamus
         dysfunction often demonstrate subnormal or absent LH response after test dose.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">androgens</span>, <span class="classification">estrogens</span>, <span class="classification">progestins</span>, <span class="classification">glucocorticoids</span> may cause false test results; <b>digoxin</b> may suppress gonadotropin levels; <span class="classification">dopamine antagonists</span>, <span class="classification">phenothiazines</span> increase <b>prolactin</b> and blunt response to gonadorelin; <b>spironolactone,</b> <b>levodopa</b> increase gonadotropin levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 35 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Hydrolyzed in plasma. <span class="typehead">Elimination:</span> Metabolites excreted in urine. <span class="typehead">Half-Life:</span> 1040 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Subnormal or absent LH response indicates pituitary or hypothalamus dysfunction.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>